Trials / Completed
CompletedNCT06147895
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Prophylactic Hepatitis B Vaccine
A Randomized, Open-labelled, Parallel, Phase 1 Clinical Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Hepatitis B Vaccine CVI-HBV-002 in Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- CHA Vaccine Institute Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety and immunogenicity of the investigational medicinal product, CVI-HBV-002.
Detailed description
A Randomized, Open-labelled, Parallel, Phase 1 clinical study to evaluate the safety, reactogenicity and immunogenicity of the hepatitis B vaccine CVI-HBV-002 in adults
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CVI-HBV-002 | Investigational Product |
Timeline
- Start date
- 2021-09-17
- Primary completion
- 2023-09-25
- Completion
- 2023-09-25
- First posted
- 2023-11-28
- Last updated
- 2024-03-25
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06147895. Inclusion in this directory is not an endorsement.